A quick peek into the report
Table of Contents
Growth Opportunities in an Era of Change
COVID-19 Major Highlights
Clinical Study and Research: Key Updates
Global COVID-19 Vaccine Landscape
Comparative Analysis of Vaccine Development
Therapeutic Outlook of COVID-19 Treatment
COVID-19 Diagnostic Test Landscape (by Target)
COVID-19 Diagnostic Test Landscape (by Technology)
Key Development in SARS-CoV-2 Diagnostics
Regulatory and Funding Activities
Major Partnership by Key Players of the COVID-19 Diagnostics Market
Monthly Snapshot
Delivered via InsightMonk, the COVID-19 monthly newsletter from the BIS Research Inc. offers a concise synopsis of the most recent scientific research on the COVID-19 pandemic. COVID-19 and SARS-CoV-2 are the subjects of a continuous flow of significant scientific discoveries. This newsletter aims to concentrate attention on recent discoveries that are most important to the public health response. The monthly epidemiological newsletter gives a summary of COVID-19-related diagnostics, treatments, and vaccinations while highlighting important statistics and trends. It also contains additional essential epidemiological data regarding the COVID-19 pandemic.
Some of the key areas covered in this monthly newsletter are:
• Latest updates pertaining to COVID-19-related diagnostics, treatments, and vaccines
• Business strategies adopted by market players in the field of COVID-19 diagnostics
• Implications of faster clinical trials and approvals of Food and Drug Administration (FDA)
• BIS Research key findings and impact analysis of COVID-19 on pharmaceutical business
How can this newsletter add value to an organization?
Key Trends: The COVID-19 newsletter comprises an overview of business strategies (partnership, collaboration, product launch, and product approval) undertaken by market players with respect to COVID-19 diagnostics, therapeutics, and vaccinations. The newsletter also comprises key developments related to COVID-19.
Global Updates: A breakdown of COVID-19 vaccine candidates in different phases has been provided, along with information on COVID-19 therapeutics as well as information related to commercialized COVID-19 diagnostics.
Overview
COVID-19 April Edition
Compared to the previous month, there were relatively fewer strategic activities reported in April 2023 in all three segments of COVID-19 diagnostics, therapeutics, and vaccines. Overall, more than 225 treatment options were reported in April 2023. Furthermore, key players evaluating Phase 3 vaccine and drug candidates included Biological E. Limited, SK Bioscience Co., Ltd., Abivax, AstraZeneca/University of Oxford, Novavax, Sinopharm, Fulcrum, Therapeutics Moderna Inc., Pfizer Inc./BioNTech SE, AstraZeneca, CureVacAG, Insmed Inc. CanSino Biological Inc., Beijing Minhai Biotechnology, Johnson & Johnson, Zydus Cadila, and Bharat Biotech. Globally, the overall confirmed cases of COVID-19 reached above 764 million as of April 30, 2023.
As of April 2023, 382 vaccine candidates were being evaluated in clinical trials in different parts of the world.
Recent Funding Activity: COVID-19 Newsletter
On April 17, 2023, the U.S. National Institutes of Health granted $11.1 million to diagnostics startup Sapphiros for the development of an over-the-counter multiplex assay for the rapid detection of respiratory syncytial virus, influenza A and B, and COVID-19. According to the company, the grant was issued under the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program.